Nutriband CEO Discusses AVERSA Technology's Role in Addressing Opioid Crisis on Podcast

Nutriband Inc. (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the opioid crisis and the company's AVERSA abuse-deterrent transdermal technology. The episode detailed how AVERSA technology is designed to reduce misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl while maintaining patient access. This discussion comes at a critical time when opioid abuse remains a significant public health concern, with transdermal patches being particularly vulnerable to misuse through methods like extraction and injection.

The technology is supported by a broad global patent portfolio, positioning Nutriband as a potential innovator in the pharmaceutical safety space. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA technology, which represents a direct application to one of the most potent and dangerous opioids currently available. According to the company, AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, suggesting broader applications beyond fentanyl alone.

This announcement matters because it addresses a critical gap in pain management safety. Traditional transdermal patches containing opioids can be manipulated by individuals seeking to abuse the medication, either by extracting the drug for injection or oral consumption or by applying multiple patches simultaneously. The AVERSA technology aims to prevent these methods of abuse while still delivering therapeutic doses to legitimate patients suffering from chronic pain. The technology's development reflects growing regulatory and public pressure on pharmaceutical companies to create abuse-deterrent formulations that maintain therapeutic efficacy while reducing diversion potential.

The implications of this technology extend beyond patient safety to include potential regulatory advantages and market differentiation. As regulatory agencies like the FDA continue to prioritize abuse-deterrent formulations, technologies like AVERSA could receive expedited review pathways or labeling advantages. Additionally, healthcare systems and insurers may show preference for abuse-deterrent formulations as they seek to reduce the costs associated with opioid misuse, including emergency department visits, addiction treatment, and lost productivity. The company's website at https://www.nutriband.com provides additional information about their pharmaceutical development focus.

For investors and stakeholders, the podcast appearance represents a strategic communication effort to raise awareness about Nutriband's technology platform during a period of heightened attention to opioid safety solutions. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. As the opioid crisis continues to evolve with shifting patterns of abuse and new synthetic opioids entering the market, technologies that can adapt to multiple drug formulations may have particular value. The discussion on the Jack Neel Podcast highlights how pharmaceutical innovation can contribute to public health solutions while creating potential business opportunities in the growing market for abuse-deterrent medications.